Selumetinib + Vinblastine for Low-Grade Glioma

"Selumetinib Sulfate is an effective treatment for advanced testicular cancer, lymphoma, hodgkins disease, and breast cancer."

"There are 67 sites running this trial, including Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center in Houston, University of Illinois in Chicago, Cardinal Glennon Children's Medical Center in Saint Louis, and other locations."

"Researchers are looking for 300 individuals, falling in the 2-25 year old age bracket, that have glioma. In addition to this broad criteria, patients must also meet the following more specific requirements: Efficacy phase: at enrollment, patients must be between 2 and 25 years old, must have a body surface area of at least 0.5 m^2 , have a two-dimensional measurable tumor volume of 1 cm^2 or greater, with tumor size including both solid and cystic components of the tumor (whether or not tumor is enhancing) + fluid attenuated inversion recovery (FLAIR) signal. Eligible hist"

"Selumetinib Sulfate was first studied in the year 2002 at Canberra Hospital. So far there have been 475 completed trials. There are currently 138 actively recruiting trials, with many of these trials being performed out of Houston, Texas."

"Yes, the clinical trial is still recruiting patients. The details were last updated on November 9th, 2022 and it was originally posted on January 8th, 2021. They are looking for 300 total patients from 67 different hospitals or clinics."

"To be eligible for this particular trial, applicants must fall between the ages of 2 and 25. Out of all the ongoing trials, 331 are for patients below 18 years old while 1244 are for senior citizens aged 65 and above."

"That is correct. The latest information on clinicaltrials.gov shows that this trial is still looking for patients. It was first posted over a year ago on 8/1/2021 and was most recently updated on 9/11/2022. There are 67 hospitals or clinics participating in the study, and they are hoping to enroll 300 people total."

"Selumetinib Sulfate Phase 3 trials have yielded some efficacy data, and there are numerous rounds of safety data, so it receives a score of 3."

"The primary goal of this clinical trial is to Event-free survival (efficacy), which will be measured over a 1 month post enrollment time frame. Secondary outcomes include Radiographic tumor response rate (efficacy) and Visual outcome comparison, which will be assessed using an exact binomial test to compare the difference in the proportion of subjects in each arm that show improvement in visual acuity per Teller Acuity assessment after 12 months of treatment. Additionally, EFS by BRAF Status will be estimated using KM methods to estimate the difference in EFS and between patients with BRAF rearranged LGG and patients with non-B"